

Chubb Insurance Australia Limited,  
Level 12, 720 Bourke Street  
Melbourne VIC 3000  
Australia  
ABN: 23 001 642 020  
AFSL: 239687

O +61 3 9242 5111  
F +61 3 9642 0909  
www.chubb.com/au

28 December 2020

# Certificate of Currency

**CHUBB**

## Clinical Trials

To Whom It May Concern

<b>Policy Number:</b>	<b>02CL441941</b>	
Insured:	Biogen Australia Pty Ltd Level 4, 2 Banfield Road, Macquarie Park, NSW 2113, Australia	
Issuing Office:	Melbourne	
Sponsor:	Biogen Idec Research Ltd Innovation House, 70 Norden Road, Maidenhead Berkshire, SL6 4AY, United Kingdom	
Class:	Clinical Trials	
Policy Period:	From: 12 November 2020 at 4:00PM local standard time To: 12 November 2022 at 4:00PM local standard time	
Cover:	Subject to all the terms and conditions of this insurance, we will pay damages and related claimant's costs that the insured becomes legally obligated to pay by reason of liability imposed by law or assumed under an insured contract, for bodily injury or property damage that happens within the Territorial Limits and in connection with your Business, caused by an occurrence to which this insurance applies.	
Limit of Liability:	AUD 10,000,000 Each Occurrence AUD 20,000,000 Each Occurrence for Trials conducted in NSW and ACT AUD 20,000,000 Annual Aggregate for all trials	
Deductible:	NIL	
Participation:	Chubb Insurance - 100%	
Study Description:	Study Title:	A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
	Protocol Number:	233AS303
	Country:	Australia

Expected Study Start Date:	01 September 2021
Expected Study Finish Date:	31 December 2027

This is a Policy summary only. Full details of this Insurance appear on the Policy Document.

Signed for and on behalf of Chubb Insurance  
Australia Limited.

Authorised Officer  
Chubb Insurance Australia Limited.  
ABN 23 001 642 020



Craigh Ansell